CNRIP1

Summary

CNRIP1 (cannabinoid receptor interacting protein 1, HGNC:24546) is a protein-coding gene on chromosome 2p14, encoding CB1 cannabinoid receptor-interacting protein 1 (Q96F85). Suppresses cannabinoid receptor CNR1-mediated tonic inhibition of voltage-gated calcium channels.

This gene encodes a protein that interacts with the C-terminal tail of cannabinoid receptor 1. Two transcript variants encoding different isoforms have been described for this gene.

Source: NCBI Gene 25927 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 67 total — 1 pathogenic
• MANE Select transcript: NM_015463

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24546
Approved symbol	CNRIP1
Name	cannabinoid receptor interacting protein 1
Location	2p14
Locus type	gene with protein product
Status	Approved
Aliases	DKFZP566K1924, CRIP1, CRIP1a, CRIP1b
Ensembl gene	ENSG00000119865
Ensembl biotype	protein_coding
OMIM	618538
Entrez	25927

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000263655, ENST00000409559, ENST00000409862, ENST00000481714, ENST00000954140

RefSeq mRNA: 7 — MANE Select: NM_015463 NM_001111101, NM_001371604, NM_001371605, NM_001371606, NM_001371607, NM_001371608, NM_015463

CCDS: CCDS1886, CCDS46311

Canonical transcript exons

ENST00000263655 — 3 exons

Exon	Start	End
ENSE00000810243	68293010	68294026
ENSE00001006457	68319222	68319949
ENSE00003478817	68317157	68317307

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 99.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.4358 / max 265.0385, expressed in 1345 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
28868	10.5301	1234
28877	7.2354	1209
28874	3.6237	1070
28870	0.7690	346
28873	0.3573	182
28876	0.2983	178
28872	0.2620	119
28875	0.1559	70
28869	0.0973	36
28871	0.0770	37

Top tissues by expression

258 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	99.53	gold quality
oocyte	CL:0000023	99.51	gold quality
middle temporal gyrus	UBERON:0002771	99.38	gold quality
Brodmann (1909) area 23	UBERON:0013554	99.14	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.38	gold quality
tendon of biceps brachii	UBERON:0008188	97.69	gold quality
primary visual cortex	UBERON:0002436	97.61	gold quality
superior frontal gyrus	UBERON:0002661	97.56	gold quality
entorhinal cortex	UBERON:0002728	97.38	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.23	gold quality
prefrontal cortex	UBERON:0000451	97.18	gold quality
frontal cortex	UBERON:0001870	97.05	gold quality
occipital lobe	UBERON:0002021	97.00	gold quality
postcentral gyrus	UBERON:0002581	96.94	gold quality
cerebral cortex	UBERON:0000956	96.88	gold quality
neocortex	UBERON:0001950	96.88	gold quality
cortical plate	UBERON:0005343	96.82	gold quality
right frontal lobe	UBERON:0002810	96.80	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.79	gold quality
parietal lobe	UBERON:0001872	96.68	gold quality
temporal lobe	UBERON:0001871	96.67	gold quality
anterior cingulate cortex	UBERON:0009835	96.44	gold quality
tibia	UBERON:0000979	96.42	gold quality
Ammon’s horn	UBERON:0001954	96.38	gold quality
cerebellar hemisphere	UBERON:0002245	96.32	gold quality
cerebellum	UBERON:0002037	96.25	gold quality
cerebellar cortex	UBERON:0002129	96.24	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.18	gold quality
amygdala	UBERON:0001876	96.17	gold quality
cardiac muscle of right atrium	UBERON:0003379	96.14	gold quality

Single-cell (SCXA)

Detected in 16 experiment(s), a significant marker in 15.

Experiment	Marker?	Max mean expression
E-MTAB-9067	yes	1313.08
E-MTAB-7407	yes	1044.46
E-CURD-112	yes	574.25
E-GEOD-76312	yes	361.78
E-CURD-6	yes	359.63
E-MTAB-10042	yes	279.90
E-MTAB-8884	yes	278.66
E-HCAD-6	yes	181.92
E-CURD-122	yes	18.58
E-MTAB-6701	yes	12.86
E-MTAB-9801	yes	9.84
E-HCAD-10	yes	9.78
E-MTAB-8410	yes	9.51
E-CURD-46	yes	5.46
E-MTAB-7303	no	565.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

49 targeting CNRIP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-219A-5P	99.91	73.36	735
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-4782-3P	99.88	73.31	735
HSA-MIR-6766-3P	99.88	73.38	732
HSA-MIR-670-5P	99.67	69.94	1565
HSA-MIR-4470	99.66	69.35	1767
HSA-MIR-3679-3P	99.64	69.88	1599
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-3120-3P	99.54	70.28	2669
HSA-MIR-4643	99.49	67.63	1791
HSA-MIR-147B-5P	99.45	70.62	2432
HSA-MIR-297	99.40	69.58	1418
HSA-MIR-4316	99.37	65.75	1360
HSA-MIR-5683	99.36	68.59	2083
HSA-MIR-4312	99.34	67.30	511
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-122B-3P	99.21	68.90	1333
HSA-MIR-21-3P	99.21	68.95	1312
HSA-MIR-10399-5P	99.17	69.87	2610
HSA-MIR-6504-3P	99.17	69.31	2891

Literature-anchored findings (GeneRIF, showing 10)

• CRIP1a can compete with beta-arrestins for interaction with C-terminal CB1R domains that could affect agonist-driven, beta-arrestin-mediated internalization of the CB1R. (PMID:27895162)
• The Arg82 and Cys126 of CRIP1b are involved in the majority of hydrogen bond interactions with the CB1 receptor and are possible key residues required for interactions between the CB1 receptor and CRIP1b (PMID:28918320)
• CNRIP1 and RUNX3 as potential DNA methylation biomarkers for CRC diagnosis and treatment (PMID:28940471)
• Through investigations of the function and structure of CRIP1a, new pharmacotherapies based upon the CRIP-CB1 receptor interaction can be designed to treat diseases such as epilepsy, motor dysfunctions and schizophrenia (PMID:31614728)
• A rare genomic duplication in 2p14 underlies autosomal dominant hearing loss DFNA58. (PMID:32337552)
• Tat-Cannabinoid Receptor Interacting Protein Reduces Ischemia-Induced Neuronal Damage and Its Possible Relationship with 14-3-3eta. (PMID:32756411)
• DNA Methylation of Cannabinoid Receptor Interacting Protein 1 Promotes Pathogenesis of Intrahepatic Cholangiocarcinoma Through Suppressing Parkin-Dependent Pyruvate Kinase M2 Ubiquitination. (PMID:32955740)
• Cannabinoid Receptor Interacting Protein 1a (CRIP1a) in Health and Disease. (PMID:33261012)
• Cannabinoid Receptor Type 1 Regulates Drug Reward Behavior via Glutamate Decarboxylase 67 Transcription. (PMID:34638827)
• Deciphering the Molecular Association of Human CRIP1a with an Agonist-Bound Cannabinoid Receptor 1. (PMID:38159053)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	cnrip1b	ENSDARG00000037337
danio_rerio	cnrip1a	ENSDARG00000091683
mus_musculus	Cnrip1	ENSMUSG00000044629
rattus_norvegicus	Cnrip1	ENSRNOG00000005326
caenorhabditis_elegans		WBGENE00017914

Protein

Protein identifiers

CB1 cannabinoid receptor-interacting protein 1 — Q96F85 (reviewed: Q96F85)

All UniProt accessions (2): Q96F85, B8ZZB8

UniProt curated annotations — full annotation on UniProt →

Function. Suppresses cannabinoid receptor CNR1-mediated tonic inhibition of voltage-gated calcium channels. Does not suppress cannabinoid receptor CNR1-mediated tonic inhibition of voltage-gated calcium channels.

Subunit / interactions. Interacts with the cannabinoid receptor CNR1 (via C-terminus). Does not interact with cannabinoid receptor CNR2.

Similarity. Belongs to the CNRIP family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96F85-1	1, CRIP1a	yes
Q96F85-2	2, CRIP1b

RefSeq proteins (7): NP_001104571, NP_001358533, NP_001358534, NP_001358535, NP_001358536, NP_001358537, NP_056278* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029204	CNRIP1	Family

Pfam: PF15043

UniProt features (3 total): chain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96F85-F1	94.94	0.92

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 524 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, BENPORATH_ES_WITH_H3K27ME3, GOBP_RESPONSE_TO_ZINC_ION, GOBP_GLAND_MORPHOGENESIS, GOBP_PROSTATE_GLAND_MORPHOGENESIS, GOBP_CELLULAR_RESPONSE_TO_UV, BASSO_B_LYMPHOCYTE_NETWORK, YANG_BREAST_CANCER_ESR1_BULK_UP, chr2p14, GOBP_CELLULAR_RESPONSE_TO_LIGHT_STIMULUS, MODULE_45, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP, SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER

GO Biological Process (3): regulation of signaling receptor activity (GO:0010469), regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission (GO:0150036), negative regulation of signaling receptor activity (GO:2000272)

GO Molecular Function (2): type 1 cannabinoid receptor binding (GO:0031718), protein binding (GO:0005515)

GO Cellular Component (5): cytoplasm (GO:0005737), plasma membrane (GO:0005886), presynapse (GO:0098793), glutamatergic synapse (GO:0098978), GABA-ergic synapse (GO:0098982)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
synapse	3
signaling receptor activity	2
cellular anatomical structure	2
regulation of signal transduction	1
regulation of molecular function	1
modulation of chemical synaptic transmission	1
trans-synaptic signaling by endocannabinoid, modulating synaptic transmission	1
regulation of signaling receptor activity	1
negative regulation of molecular function	1
cannabinoid receptor binding	1
binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

524 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CNRIP1	CNR1	P21554	745
CNRIP1	SEPTIN9	Q9UHD8	660
CNRIP1	SNAPIN	O95295	606
CNRIP1	DAGLB	Q8NCG7	555
CNRIP1	DAGLA	Q9Y4D2	553
CNRIP1	VIM	P08670	552
CNRIP1	SPART	Q8N0X7	479
CNRIP1	ABHD6	Q9BV23	478
CNRIP1	DNAJC14	Q6Y2X3	459
CNRIP1	FBXO48	Q5FWF7	456
CNRIP1	CDO1	P78513	448
CNRIP1	LRRC28	Q86X40	420
CNRIP1	ZSCAN18	Q8TBC5	399
CNRIP1	PLD6	Q8N2A8	393
CNRIP1	ADHFE1	Q8IWW8	392

IntAct

23 interactions, top by confidence:

A	B	Type	Score
CNRIP1	PRTFDC1	psi-mi:“MI:0915”(physical association)	0.560
YIF1A	CNRIP1	psi-mi:“MI:0915”(physical association)	0.560
ZFP41	LRP4	psi-mi:“MI:0914”(association)	0.530
PGLYRP1	IFNA2	psi-mi:“MI:0914”(association)	0.530
C20orf203	POTEI	psi-mi:“MI:0914”(association)	0.530
	TK2	psi-mi:“MI:0915”(physical association)	0.400
CNRIP1	GCH1	psi-mi:“MI:0915”(physical association)	0.370
SST	ATP1A2	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
RBM18	GSN	psi-mi:“MI:0914”(association)	0.350
CNRIP1	UTP4	psi-mi:“MI:0914”(association)	0.350
MAPT	PITPNM1	psi-mi:“MI:2364”(proximity)	0.270
MAPT		psi-mi:“MI:2364”(proximity)	0.270
CNRIP1	PRTFDC1	psi-mi:“MI:0915”(physical association)	0.000
CNRIP1	YIF1A	psi-mi:“MI:0915”(physical association)	0.000
RUNX1	CNRIP1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (35): KCTD5 (Affinity Capture-MS), CIRH1A (Affinity Capture-MS), CNRIP1 (Affinity Capture-MS), CNRIP1 (Affinity Capture-MS), CNRIP1 (Affinity Capture-MS), CNRIP1 (Affinity Capture-MS), CIRH1A (Affinity Capture-MS), CNRIP1 (Affinity Capture-MS), KCTD2 (Affinity Capture-MS), CNRIP1 (Affinity Capture-MS), CNRIP1 (Affinity Capture-MS), CNRIP1 (Affinity Capture-MS), CNRIP1 (Two-hybrid), CNRIP1 (Affinity Capture-Western), CNRIP1 (Two-hybrid)

ESM2 similar proteins: B3M1E1, B3P4N5, B4GZ20, B4HJC0, B4NKI9, B4PVH6, B4QVW6, H2KYU6, O08619, O57538, P00488, P10493, P10759, P12260, P22735, P22758, P23606, P29458, P34501, P52183, P79734, P79820, P91309, Q01432, Q05187, Q17QM9, Q24151, Q29B63, Q29RZ2, Q41969, Q5M8N0, Q5R4L5, Q66K08, Q6GQ76, Q6MVH7, Q7KRR5, Q8BH61, Q92143, Q95QZ9, Q96F85

Diamond homologs: Q17QM9, Q5M7A7, Q5M8N0, Q96F85, Q9GKT6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

67 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	49
Likely benign	0
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3252105	NC_000002.12:g.68218674_68450455dup	Pathogenic

SpliceAI

692 predictions. Top by Δscore:

Variant	Effect	Δscore
2:68294027:C:CC	acceptor_gain	1.0000
2:68319220:A:AC	donor_gain	1.0000
2:68319221:C:CC	donor_gain	1.0000
2:68319221:CTCGA:C	donor_gain	1.0000
2:68317275:A:T	acceptor_gain	0.9900
2:68294024:GAAC:G	acceptor_loss	0.9800
2:68294028:T:G	acceptor_loss	0.9800
2:68319320:CACCT:C	acceptor_gain	0.9800
2:68294023:TGAA:T	acceptor_gain	0.9700
2:68317150:GCCTT:G	donor_loss	0.9700
2:68317151:CCTT:C	donor_loss	0.9700
2:68317152:CTT:C	donor_loss	0.9700
2:68317153:TTA:T	donor_loss	0.9700
2:68317154:TACCG:T	donor_loss	0.9700
2:68317155:A:T	donor_loss	0.9700
2:68317156:C:A	donor_loss	0.9700
2:68317156:CCGG:C	donor_gain	0.9700
2:68318415:T:TA	donor_gain	0.9700
2:68319221:CT:C	donor_gain	0.9700
2:68319324:T:C	acceptor_gain	0.9700
2:68306985:T:TC	acceptor_gain	0.9600
2:68318400:TC:T	donor_gain	0.9600
2:68318401:C:CT	donor_gain	0.9600
2:68319258:A:C	donor_gain	0.9600
2:68294024:GAA:G	acceptor_gain	0.9500
2:68294025:AA:A	acceptor_gain	0.9500
2:68316882:A:C	donor_gain	0.9500
2:68317155:A:AC	donor_gain	0.9500
2:68317156:C:CC	donor_gain	0.9500
2:68318448:T:A	donor_gain	0.9500

AlphaMissense

1073 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:68293918:A:G	C147R	1.000
2:68293947:C:A	G137V	1.000
2:68293947:C:T	G137E	1.000
2:68293948:C:G	G137R	1.000
2:68293948:C:T	G137R	1.000
2:68293960:G:C	H133D	1.000
2:68293985:C:A	K124N	1.000
2:68293985:C:G	K124N	1.000
2:68293986:T:A	K124M	1.000
2:68293987:T:C	K124E	1.000
2:68293987:T:G	K124Q	1.000
2:68293996:A:G	W121R	1.000
2:68293996:A:T	W121R	1.000
2:68294013:C:T	G115E	1.000
2:68294014:C:A	G115W	1.000
2:68317182:C:G	R102P	1.000
2:68317183:G:C	R102G	1.000
2:68317188:C:T	G100E	1.000
2:68317222:A:C	Y89D	1.000
2:68319258:A:T	V48D	1.000
2:68319282:A:G	L40P	1.000
2:68319284:C:A	K39N	1.000
2:68319284:C:G	K39N	1.000
2:68319286:T:C	K39E	1.000
2:68319291:G:A	T37I	1.000
2:68319305:G:C	F32L	1.000
2:68319305:G:T	F32L	1.000
2:68319306:A:C	F32C	1.000
2:68319306:A:G	F32S	1.000
2:68319307:A:C	F32V	1.000

dbSNP variants (sampled 300 via entrez): RS1000006430 (2:68304114 G>A,T), RS1000008838 (2:68295672 T>C), RS1000049874 (2:68286374 A>G), RS1000251477 (2:68293766 A>T), RS1000269640 (2:68289591 C>A,G,T), RS1000289037 (2:68302099 A>T), RS1000433927 (2:68306869 A>G,T), RS1000462512 (2:68319907 G>A), RS1000463554 (2:68306640 G>A,T), RS1000616964 (2:68313068 G>T), RS1000660548 (2:68302355 T>G), RS1000871818 (2:68291111 G>A), RS1000932547 (2:68312063 T>C), RS1000963751 (2:68311787 A>G), RS1000982095 (2:68300511 G>A,C)

Disease associations

OMIM: gene MIM:618538 | disease phenotypes: MIM:615654

GenCC curated gene-disease

Mondo (2): breast ductal adenocarcinoma (MONDO:0005590), autosomal dominant nonsyndromic hearing loss 58 (MONDO:0014293)

Orphanet (1): Rare autosomal dominant non-syndromic sensorineural deafness type DFNA (Orphanet:90635)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST007267_88	Systolic blood pressure	5.000000e-10
GCST007325_227	General risk tolerance (MTAG)	4.000000e-09
GCST90002394_486	Monocyte percentage of white cells	7.000000e-10

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0008579	risk-taking behaviour
EFO:0007989	monocyte percentage of leukocytes

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, decreases expression, affects cotreatment	7
trichostatin A	affects cotreatment, increases expression	3
sodium arsenite	affects cotreatment, increases expression	3
entinostat	increases expression, affects cotreatment	2
(+)-JQ1 compound	decreases expression	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Air Pollutants	increases abundance, increases expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Aflatoxin B1	decreases methylation, increases expression	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
methylmercuric chloride	decreases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	affects cotreatment, increases methylation	1
decabromobiphenyl ether	increases expression	1
arsenite	affects binding, increases reaction	1
3,4,5,3’,4’-pentachlorobiphenyl	decreases expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression, decreases expression	1
Temozolomide	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	increases expression	1
Benzo(a)pyrene	increases methylation	1
Diethylhexyl Phthalate	decreases expression	1
Lead	affects expression	1
Rotenone	decreases expression	1
Tretinoin	affects cotreatment, increases expression	1
Cyclosporine	increases expression	1

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery